Stryker Corporation shares have risen 13.6% in the past three months, outpacing the Zacks Medical sector's 12.9% gain and the S&P 500's 1.7% advance. The move has coincided with a sharper operating recovery after a difficult first quarter. Second-quarter organic sales increased 9%, while adjusted earnings rose 17.9% to $3.69 per share. Management said the company exited the quarter with regained momentum after the March cybersecurity disruption. Stryker trades at 21.6 times forward 12-month earnings, above the Zacks sub-industry's 17.5 times multiple but below its own five-year median of 26 times.
